PinPoint Get PinPoint on the App Store

GLP-1 & metabolic / Compound guide

Tirzepatide guide

Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in metabolic disease and sold as Mounjaro and Zepbound.[2] PinPoint's generic entry uses labeled subcutaneous pharmacokinetic references to support unit conversion and modeled levels between logged doses.[1]

PINPOINT EDITORIAL · UPDATED 05 OCT 2026
FDA-labeled presentation · 120 h model input

Editorial still life for glp-1 & metabolic research guides

ILLUSTRATION / COMPOUND LIBRARY SERIES

At a glance

Tirzepatide library factsGLP-1 & metabolic. Routes: subcutaneous. Half-life model input: 120 hours. Package: 10 mg / package. FDA-labeled presentation. CATEGORYROUTES IN LIBRARYHALF-LIFE MODEL INPUTTYPICAL PACKAGERESEARCH STATUS GLP-1 & metabolicsubcutaneous120 hours10 mg / packageFDA-labeled presentation SOURCE / PINPOINT COMPOUND LIBRARY

Read the record in context

The tirzepatide facts connect two receptor targets to one generic record. The 120-hour time scale comes from prescribing information, whereas the 10 mg package is a catalog listing. Keeping those origins separate avoids reading a supplier's container as a labeled device or research amount.[1]

What the research says

The Mounjaro label describes tirzepatide as a peptide acting at both GIP and GLP-1 receptors. Its pharmacokinetic program compared healthy participants with people who had type 2 diabetes and found similar disposition. Investigators followed plasma concentrations after subcutaneous administration to characterize exposure and elimination.[2]

The label reports approximately 80% absolute bioavailability, a peak-concentration window of eight to 72 hours, and an elimination half-life of about five days. Exposure increases proportionally with dose. The wide peak window is part of the measured population description, rather than one fixed time for every participant.[2][1]

Clinical studies in the same document evaluate glycemic outcomes in adults with type 2 diabetes, using measures such as HbA1c and body weight. Those clinical endpoints answer different questions from plasma drug concentrations. The labeled solution used in those programs is distinct from the research-catalog package retained in the library snapshot.[2][1]

Cited amounts

The Mounjaro label lists a 5 mg/0.5 mL single-dose presentation. This approved solution supplies the primary arithmetic example below. The library separately preserves a 10 mg research-catalog package; that supplier amount is not the labeled solution or proof of an equivalent formulation.[6][1]

Explore the Tirzepatide dosing chart

Half-life and timing

With 120 hours per halving, a one-starting-amount illustration reaches 50% at day five and 25% at day ten. The next three halvings place 12.5%, 6.25%, and 3.125% at days 15, 20, and 25. This sequence is deliberately simpler than a modeled history containing multiple entries. It also omits the eight- to 72-hour concentration-peak window described by the source. A graph's endpoint cannot answer when an individual has completely eliminated tirzepatide.[1][5]

Tirzepatide: modeled fraction over five half-livesStarting at 100 percent, the model halves each 120 hours. After 600 hours, 3.125 percent remains. This is arithmetic, not a measured concentration. ELAPSED HOURS / MODELED STARTING AMOUNT 0 h100%120 h50%240 h25%360 h12.5%480 h6.25%600 h3.125% Explore the Tirzepatide half-life model

Reconstitution

For the labeled Mounjaro 5 mg/0.5 mL presentation, dividing total amount by supplied liquid volume gives 10 mg/mL. The half-milliliter is already present in the product; it is not water to add. This verifies a concentration without choosing an administration amount or changing how the device is used. The library catalog vial is a separate presentation and is not converted into a labeled product by sharing the same generic molecule.[6]

5 mg ÷ 0.5 mL = 10 mg/mL
Open Tirzepatide conversion math

Tracking it in PinPoint

From a reference to a record

Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Enter vial size in mg, mcg, or IU and water volume for instant concentration and syringe units. Track vials and prefilled pens side by side.[4]

The Home curve models your levels between doses from published half-life data. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.

Get PinPoint on the App Store

Frequently asked questions

What is the half-life of tirzepatide?
The library stores 120 hours, or five days, from its labeled subcutaneous reference. Five modeled half-lives span 600 hours. That arithmetic leaves 3.125% of the starting model amount, so it does not mean complete elimination or provide a personal waiting-period rule.[1][2]
What information does a tirzepatide dosing calculator need?
It needs independently known quantities, not merely the drug name. In a liquid example those include total compound, final volume, and the amount being converted. The calculator cannot obtain a clinically selected amount from the library's five-day reference.[1][5]
Does a tirzepatide half-life chart include the concentration peak?
The bar on this page begins with an abstract starting quantity and repeatedly halves it. The label's concentration-peak window concerns absorption after administration. That additional process is intentionally absent from this simple elimination illustration, so the bar is not a complete exposure profile.[1][5]
Can a peptide tracker app record Tirzepatide?
PinPoint's compound library includes Tirzepatide. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][4]

Sources

Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.

  1. PinPoint compound library, TirzepatideSnapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
  2. DailyMed prescribing informationIdentity and research summary checked against this document on 5 October 2026. Clinical pharmacology and product-description sections.Retrieved 2026-10-05 · library-reference
  3. Supplier catalog package referencePackage amount only; not a clinical amount or endorsement.Retrieved 2026-10-05 · supplier
  4. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
  5. Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic
  6. Approved product label: package presentationVerified 5 October 2026. Separately labeled presentation; does not validate a research-catalog vial.Retrieved 2026-10-05 · product-label